An Australian technology entrepreneur has established a startup called Gamgee following widespread attention to his account of using artificial intelligence tools to develop a personalized cancer vaccine for his dog. Paul Conyngham utilized ChatGPT, Grok, and other AI systems to design the treatment for his pet, and the story generated significant public interest earlier this year.
Gamgee aims to provide customized messenger RNA cancer vaccines specifically for dogs, though the company’s vision extends considerably further. According to its website, the startup intends to leverage artificial intelligence and genetic science to create individualized treatments for various diseases across multiple species, with human applications also on the horizon. The company is backed by the prominent technology incubator Y Combinator and is currently recruiting participants for initial clinical trials in Australia.
The startup’s origin story centers on Rosie, Conyngham’s Staffordshire bull terrier-Shar Pei mix, whose tumors reportedly shrank following the treatment. Gamgee claims the vaccine can be produced within approximately four weeks and requires minimal time commitment from veterinarians. However, scientific experts have raised questions about the claims surrounding Rosie’s case, noting that the exact contribution of the mRNA vaccine remains unclear since it was administered alongside other therapies, making it impossible to definitively attribute her improvement to any single treatment.
Gamgee is collaborating with research institutions at the University of Queensland and the University of New South Wales in Australia as it develops its platform for broader clinical application.
Originally reported by Theverge →
About the Author
